Literature DB >> 18245517

Partial cancer prevalence in Japan up to 2020: estimates based on incidence and survival data from population-based cancer registries.

Nana Tabata1, Yuko Ohno, Rieko Matsui, Hiromi Sugiyama, Yuri Ito, Hideaki Tsukuma, Akira Oshima.   

Abstract

Measuring cancer prevalence in Japan has been difficult because population-based cancer registries have been conducted in limited areas. The purpose of this study was to estimate cancer prevalence in Japan from 1995 to 2020 for 5-year periods based on selected population-based cancer registry data. 1-, 2-3-, 4-5- and 5-year partial prevalence were estimated using incidence and survival data. Incidence and survival were calculated using data from selected cancer registries. We estimated the cancer survival by age group, primary site, and sex using the mixture cure fraction model. Kaplan-Meier estimates were applied to subgroups for which the survival did not converge to the estimated model. We projected that 1-year cancer prevalence for all sites would increase from 209 971 to 367 354 for men and from 164 622 to 275 776 for women, that 2-3-year prevalence would increase from 288 284 to 508 731 for men and from 255 684 to 418 630 for women, that 4-5-year prevalence would increase from 216 834 to 379 461 in men and from 211 764 to 342 031 in women, and that 5-year prevalence would increase from 715 089 to 1 255 546 in men and from 632 070 to 1 036 437 in women. This study is the first estimate of cancer prevalence in the future in Japan.

Entities:  

Mesh:

Year:  2008        PMID: 18245517     DOI: 10.1093/jjco/hym156

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

1.  High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes.

Authors:  Natsuo Tomita; Norihito Soga; Yuji Ogura; Norio Hayashi; Takumi Kageyama; Makoto Ito; Yutaro Koide; Maiko Yoshida; Kana Kimura; Chiyoko Makita; Hiroyuki Tachibana; Takeshi Kodaira
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-02       Impact factor: 4.553

2.  Projections of cancer prevalence in the United Kingdom, 2010-2040.

Authors:  J Maddams; M Utley; H Møller
Journal:  Br J Cancer       Date:  2012-08-14       Impact factor: 7.640

3.  Magnetic nanoparticles of Fe3O4 enhance docetaxel-induced prostate cancer cell death.

Authors:  Akiko Sato; Naoki Itcho; Hitoshi Ishiguro; Daiki Okamoto; Naohito Kobayashi; Kazuaki Kawai; Hiroshi Kasai; Daisuke Kurioka; Hiroji Uemura; Yoshinobu Kubota; Masatoshi Watanabe
Journal:  Int J Nanomedicine       Date:  2013-08-19

4.  Cancer Prevalence in Aichi, Japan for 2012: Estimates Based on Incidence and Survival Data from Population-Based Cancer Registry

Authors:  Hiroko Nakagawa-Senda; Michiyo Yamaguchi; Tomohiro Matsuda; Kayoko Koide; Yoshinobu Kondo; Hideo Tanaka; Hidemi Ito
Journal:  Asian Pac J Cancer Prev       Date:  2017-08-27

5.  Coffee consumption and the risk of prostate cancer: the Ohsaki Cohort Study.

Authors:  Q Li; M Kakizaki; Y Sugawara; Y Tomata; T Watanabe; Y Nishino; I Tsuji
Journal:  Br J Cancer       Date:  2013-05-14       Impact factor: 7.640

6.  Incidence of multiple primary cancers and interval between first and second primary cancers.

Authors:  Mai Utada; Yuko Ohno; Megumi Hori; Midori Soda
Journal:  Cancer Sci       Date:  2014-06-27       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.